Edgewise Therapeutics (NASDAQ:EWTX) Releases Earnings Results, Misses Expectations By $0.06 EPS

Posted by George Bondi on Aug 8th, 2026

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) posted its earnings results on Thursday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.06), FiscalAI reports.

Edgewise Therapeutics Stock Down 2.0%

EWTX traded down $0.90 on Friday, hitting $43.52. 1,477,480 shares of the company traded hands, compared to its average volume of 1,124,887. The company has a 50 day moving average of $39.45 and a 200-day moving average of $34.09. The stock has a market capitalization of $4.68 billion, a PE ratio of -23.52 and a beta of 0.30. Edgewise Therapeutics has a 12-month low of $12.30 and a 12-month high of $48.40.

Insiders Place Their Bets

In other Edgewise Therapeutics news, insider Alan J. Russell sold 200,000 shares of Edgewise Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $39.41, for a total value of $7,882,000.00. Following the transaction, the insider directly owned 24,555 shares in the company, valued at approximately $967,712.55. This trade represents a 89.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 21.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in EWTX. Invesco Ltd. raised its holdings in Edgewise Therapeutics by 14.2% during the fourth quarter. Invesco Ltd. now owns 75,438 shares of the company’s stock worth $1,872,000 after purchasing an additional 9,382 shares in the last quarter. Oracle Investment Management Inc. purchased a new stake in Edgewise Therapeutics in the 4th quarter valued at approximately $951,000. KVP Capital Advisors LP purchased a new stake in Edgewise Therapeutics in the 4th quarter valued at approximately $3,300,000. XTX Topco Ltd acquired a new position in Edgewise Therapeutics during the 4th quarter worth approximately $1,380,000. Finally, VARCOV Co. acquired a new position in Edgewise Therapeutics during the 4th quarter worth approximately $249,000.

Analyst Ratings Changes

EWTX has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edgewise Therapeutics in a report on Friday, July 17th. Raymond James Financial reissued a “strong-buy” rating and set a $66.00 target price on shares of Edgewise Therapeutics in a research report on Monday, June 1st. Truist Financial set a $52.00 target price on Edgewise Therapeutics in a research note on Wednesday, May 6th. Royal Bank Of Canada upped their price target on Edgewise Therapeutics from $48.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday, June 17th. Finally, Wedbush raised their price target on Edgewise Therapeutics from $46.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.75.

Check Out Our Latest Stock Report on Edgewise Therapeutics

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.